<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>20(8)</volume><submitter>Yoon CS</submitter><pubmed_abstract>Bacterial co-infection has been associated with adverse outcomes in patients with COVID-19. Streptococcus pneumoniae is a common cause of community-acquired pneumonia and may contribute to poor clinical outcomes when co-detected in COVID-19 patients. This study aimed to investigate the clinical significance of pneumococcal positivity in hospitalized patients with COVID-19. We conducted a retrospective analysis of adult patients hospitalized with COVID-19 at two tertiary care centers. Pneumococcal positivity was defined by either a positive urinary antigen test or multiplex real-time polymerase chain reaction. Disease severity of COVID-19 pneumonia was assessed using the pneumonia severity index and CURB-65 scoring systems. Propensity score matching and multivariable logistic regression were used to adjust for confounders and identify independent risk factors for mortality. Among 280 patients, 65 pneumococcus-positive patients were matched with 65 pneumococcus-negative patients after propensity score matching. In the overall matched cohort, pneumococcal positivity was not significantly associated with in-hospital mortality. However, in patients with severe disease (n = 156), defined as pneumonia severity index >130 or CURB-65 ≥ 3, mortality was significantly higher in pneumococcus-positive patients (n = 39) than in pneumococcus-negative patients (53.8% vs. 29.1%, p = 0.009). In the multivariable analysis of this subgroup, pneumococcal positivity (odds ratio, 4.050; 95% confidence interval, 1.285-12.765; p = 0.017) and high-flow oxygen therapy (odds ratio, 6.510; 95% confidence interval, 1.847-22.944; p = 0.004) were independently associated with mortality. Detection of S. pneumoniae by urinary antigen test or multiplex polymerase chain reaction was associated with increased mortality in patients hospitalized with severe COVID-19.</pubmed_abstract><journal>PloS one</journal><pagination>e0329474</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12370052</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>The influence of pneumococcal positivity on clinical outcomes among patients hospitalized with COVID-19: A retrospective cohort study.</pubmed_title><pmcid>PMC12370052</pmcid><pubmed_authors>Kho BG</pubmed_authors><pubmed_authors>Kim YI</pubmed_authors><pubmed_authors>Park HY</pubmed_authors><pubmed_authors>Yoon CS</pubmed_authors><pubmed_authors>Lee JK</pubmed_authors><pubmed_authors>Park HK</pubmed_authors><pubmed_authors>Kim TO</pubmed_authors><pubmed_authors>Lim SC</pubmed_authors><pubmed_authors>Kwon YS</pubmed_authors><pubmed_authors>Shin HJ</pubmed_authors></additional><is_claimable>false</is_claimable><name>The influence of pneumococcal positivity on clinical outcomes among patients hospitalized with COVID-19: A retrospective cohort study.</name><description>Bacterial co-infection has been associated with adverse outcomes in patients with COVID-19. Streptococcus pneumoniae is a common cause of community-acquired pneumonia and may contribute to poor clinical outcomes when co-detected in COVID-19 patients. This study aimed to investigate the clinical significance of pneumococcal positivity in hospitalized patients with COVID-19. We conducted a retrospective analysis of adult patients hospitalized with COVID-19 at two tertiary care centers. Pneumococcal positivity was defined by either a positive urinary antigen test or multiplex real-time polymerase chain reaction. Disease severity of COVID-19 pneumonia was assessed using the pneumonia severity index and CURB-65 scoring systems. Propensity score matching and multivariable logistic regression were used to adjust for confounders and identify independent risk factors for mortality. Among 280 patients, 65 pneumococcus-positive patients were matched with 65 pneumococcus-negative patients after propensity score matching. In the overall matched cohort, pneumococcal positivity was not significantly associated with in-hospital mortality. However, in patients with severe disease (n = 156), defined as pneumonia severity index >130 or CURB-65 ≥ 3, mortality was significantly higher in pneumococcus-positive patients (n = 39) than in pneumococcus-negative patients (53.8% vs. 29.1%, p = 0.009). In the multivariable analysis of this subgroup, pneumococcal positivity (odds ratio, 4.050; 95% confidence interval, 1.285-12.765; p = 0.017) and high-flow oxygen therapy (odds ratio, 6.510; 95% confidence interval, 1.847-22.944; p = 0.004) were independently associated with mortality. Detection of S. pneumoniae by urinary antigen test or multiplex polymerase chain reaction was associated with increased mortality in patients hospitalized with severe COVID-19.</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025</publication><modification>2026-05-07T05:00:58.252Z</modification><creation>2026-04-07T22:33:05.398Z</creation></dates><accession>S-EPMC12370052</accession><cross_references><pubmed>40839694</pubmed><doi>10.1371/journal.pone.0329474</doi></cross_references></HashMap>